Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO6870810 + Atezolizumab in Advanced Ovarian Cancer or TNBC
NCT03292172Phase 1Terminated
- Sponsor
- Roche
- Start
- Nov 2017
- Primary completion
- Feb 2019
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of RO-6870810 in ovarian cancer and triple-negative breast cancer (TNBC) (4 arms), sponsored by Roche. Primary endpoints: Percentage of Participants With Dose Limiting Toxicities, Percentage of Participants With Adverse Events up to 22 months and 2 more. Started Nov 2017; status: terminated.
02
Drugs
RO-6870810
03
Conditions
ovarian cancertriple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03292172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03292172.